Puma Biotechnology (PBYI) director gets 27K RSUs, sells 8.1K shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Puma Biotechnology director Brian M. Stuglik reported both an equity grant and a share sale. On June 11, 2026, he acquired 27,000 shares of common stock at $0.00 per share as a grant of Restricted Stock Units that vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, subject to continued service. On June 12, 2026, he executed an open-market sale of 8,100 common shares at a weighted average price of $7.1989 per share, in multiple trades between $6.98 and $7.32, under a Rule 10b5-1(c) trading plan adopted on March 12, 2025. Following these transactions, he directly holds 113,858 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 8,100 shares ($58,311)
Net Sell
2 txns
Insider
Stuglik Brian M
Role
null
Sold
8,100 shs ($58K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 8,100 | $7.1989 | $58K |
| Grant/Award | Common Stock | 27,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 113,858 shares (Direct, null)
Footnotes (1)
- Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Key Figures
Shares sold: 8,100 shares
Weighted average sale price: $7.1989 per share
RSU grant size: 27,000 shares
+2 more
5 metrics
Shares sold
8,100 shares
Open-market sale of common stock on June 12, 2026
Weighted average sale price
$7.1989 per share
Common stock sale on June 12, 2026; trades $6.98–$7.32
RSU grant size
27,000 shares
Restricted Stock Unit grant on June 11, 2026
Post-transaction holdings
113,858 shares
Common stock directly owned after reported transactions
10b5-1 plan adoption date
March 12, 2025
Plan governing June 12, 2026 share sale
Key Terms
Restricted Stock Units, Rule 10b5-1(c) plan, weighted average price, open-market sale
4 terms
Restricted Stock Units financial
"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1(c) plan regulatory
"Adoption date of referenced 10b5-1(c) plan is: 03-12-2025"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transactions did PBYI director Brian Stuglik report?
Brian M. Stuglik reported a stock grant and a sale. He received 27,000 Puma Biotechnology common shares as a Restricted Stock Unit grant, then sold 8,100 shares in the open market at a weighted average price of $7.1989 per share.
What equity award did PBYI grant to director Brian Stuglik?
Puma Biotechnology granted Brian M. Stuglik 27,000 shares of common stock as Restricted Stock Units at a grant price of $0.00. These RSUs vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting.
When do Brian Stuglik’s Puma Biotechnology RSUs vest?
The Restricted Stock Units vest in full on the earlier of the one-year anniversary of the grant date or the annual shareholder meeting following the grant date. Vesting is conditioned on his continued service with Puma Biotechnology through the applicable vesting date.